TCL Archive NCI Makes First NRS Award – 13 Institution Grants; 150 Individuals Pending: Lepovetsky Training Chief April 4, 1975
TCL Archive FDA approval of two colon cancer therapies triggers discussion among researchers, clinicians about best treatment and clinical trial designs. CMS reimbursement pending; costs to U.S. of the new drugs could be billions per year, but some predict dramatic increases in survival. March 5, 2004
TCL Archive The shadow of Iressa lingered over the FDA Oncologic Drugs Advisory Committee as the panel voted down Genasense (Genta Inc.) and RSR13 (Allos Therapeutics Inc.) at its May 3 meeting. If anyone thought the bar had been lowered for drug approvals, they were mistaken. May 7, 2004
TCL Archive Dana-Farber Accepts Responsibility For Death Of One Patient, Harm To Another March 31, 1995
